Peripheral Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients

A. Kessinger, Julie M. Vose, Philip J. Bierman, Michael Bishop, James O. Armitage

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Transplantation of circulating progenitor/stem cells collected before and stored during administration of marrow-ablative antitumor therapy has restored sustained hematopoiesis for patients with a variety of malignancies. One of the most common diseases so treated is refractory or relapsed non-Hodgkin's lymphoma (NHL). Autologous peripheral stem cell transplantation (PSCT) often has been used rather than autologous bone marrow transplantation (ABMT) because NHL commonly involves the bone marrow, and because, in some situations, PSCT provides earlier engraftment than ABMT. Between July 1986 and September 1992, 170 adult patients with refractory or relapsed NHL were treated with high-dose therapy and PSCT at the University of Nebraska Medical Center (UNMC). With a median follow-up of 469 days for the evaluable survivors, the actuarial progression-free survival for 167 patients at 6 years after PSCT was 30%. High-dose therapy and PSCT for NHL patients has resulted in long-term progression-free survival and probably cure for some patients. The role of PSCT in this disease continues to evolve.

Original languageEnglish (US)
Pages (from-to)361-362
Number of pages2
JournalJournal of hematotherapy
Issue number3
StatePublished - 1993

ASJC Scopus subject areas

  • Immunology
  • Hematology


Dive into the research topics of 'Peripheral Stem Cell Transplantation in Non-Hodgkin's Lymphoma Patients'. Together they form a unique fingerprint.

Cite this